[Pharmacological properties of peptide derivatives of 5-methoxytrayptamine].
D000409:Alanine; D000613:Aminobutyrates; D000661:Amphetamine / Q000037:antagonists & inhibitors; D000818:Animals; D001120:Arginine; D001158:Arteries / Q000187:drug effects; D001775:Blood Circulation / Q000187:drug effects*; D002415:Cats; D003553:Cystine; D003864:Depression, Chemical; D004231:Diuresis / Q000187:drug effects*; D004357:Drug Synergism; D005973:Glutamine; D005998:Glycine; D006591:Hexobarbital / Q000494:pharmacology; D008297:Male; D008715:Methionine; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects*; D010455:Peptides / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D012119:Respiration / Q000187:drug effects*; D013268:Stimulation, Chemical; D014363:Tryptamines / Q000494:pharmacology* / Q000633:toxicity; D014633:Valine
D000613:Aminobutyrates; D010455:Peptides; D014363:Tryptamines; D005973:Glutamine; D003553:Cystine; D001120:Arginine; D008715:Methionine; D006591:Hexobarbital; D000661:Amphetamine; D014633:Valine; D000409:Alanine; D005998:Glycine
Farmakologicheskie svoĭstva peptidnykh proizvodnykh 5-metoksitriptamina.